Condition: HIV/AIDS · Sponsor: ANRS, Emerging Infectious Diseases
The purpose of this study is to evaluate the efficacy, acceptability, and safety of a simplified event-driven pre-exposure prophylaxis of HIV based on oral TAF/FTC in HIV-uninfected cisgender men who have sex with men (MSM). Primary objective: To assess the efficacy of emtricitabine 200 mg + tenofovir alafenamide 25 mg (F/TAF), taken 2 to 24 hours before sexual intercourse followed by a second dose 24 hours after the first intake, in reducing the risk of HIV acquisition in MSM relative to the background HIV incidence rate.
This description comes directly from the study's public registry record.
Geoffroy LIEGEON, MD, PhD · +33 142494991 · geoffroy.liegeon@aphp.fr
Gonzague JOURDAIN, MD, PhD · : +66 8 1883 0065 · gonzague.jourdain@phpt.org
Always discuss trial participation with your own doctor first.
| AP-HP - Hospital Lariboisière | Paris, France | Recruiting |
| AP-HP - Hôpital Saint-Louis | Paris, France | Recruiting |
| MPlus Clinic | Chiang Mai, Thailand | Recruiting |
| STIs Clinic of the Office of Disease Prevention and Control Region 1 | Chiang Mai, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05813964